Korsana Biosciences Inc. (KRSA)
KRSA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1755237/000119312526132193/0001193125-26-132193-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | KRSA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001755237 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | MA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.1M |
| Net income | -$3.5M |
| Operating income | -$5.0M |
| Net margin | -170.1% |
| Operating margin | -239.8% |
| Revenue growth | +3.7% |
| Cash | $3.2M |
| Total assets | $10.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 717.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Some of the more significant risks and uncertainties we face include the following: We will need to raise additional capital, and if we are unable to do so when needed, that could raise substantial doubt about our ability to continue as a going concern;" | 10-Q 2026-11-05 |
| Cash and burn | $456.2M cash; operating cash flow -$10.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 45,541,358 (2026-11-02); 3,925,314 a year earlier; 2,445,096 three years earlier. 1y figure adjusted for splits (1-for-7 overall); 3y figure adjusted for splits (1-for-7 overall). | Cover page 2026-11-02 |
| Reverse splits, 3 years | 1; latest 1-for-7 on 2026-09-09 | Source 2026-09-09 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-04-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$46.4M | -$46.8M | $456.2M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $0 | -$17.4M | -$1.4M | $1.4M | No debt tags | $1.9M | 10-Q 2026-08-04 |
| Q1 2026 2026-03-31 | $0 | -$13.5M | -$1.2M | $2.8M | No debt tags | $2.0M | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $1.0M | $18.4M | $8.5M | $154.1M | No debt tags | $2.1M | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | $875K | -$21.7M | -$10.3M | $4.6M | No debt tags | $2.9M | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | $93K | -$152K | -$503K | $3.0M | No debt tags | $2.2M | 10-Q 2026-08-04 |
| Q1 2025 2025-03-31 | $81K | -$73K | -$968K | $3.6M | No debt tags | $2.1M | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $1.8M | $530K | $360K | $3.2M | No debt tags | $2.0M | 10-K 2026-03-30 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-07-24 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEF 14A | 2026-10-15 |
Source: SEC EDGAR submissions feed, 397 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.9% |
| 1 month | -0.0% |
| 3 months | +15.6% |
| Year to date | +256.0% |
| 1 year | +214.0% |
| From 52-week high | -29.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RAPP | Rapport Therapeutics Inc. | $24.82 | -5.09% | $1.5B |
| PCRX | Pacira BioSciences Inc. | $36.48 | +0.05% | $1.5B |
| SLS | SELLAS Life Sciences Group Inc. | $7.47 | -4.96% | $1.5B |
| NBTX | Nanobiotix S.A. | $28.54 | -6.90% | $1.5B |
| QURE | uniQure N.V. | $21.88 | -8.11% | $1.5B |
| PGEN | Precigen Inc. | $4.30 | -5.29% | $1.5B |
| ADRX | ADARx Pharmaceuticals Inc. | $14.00 | -1.41% | $1.6B |
| PAHC | Phibro Animal Health Corporation | $35.02 | -2.64% | $1.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier